Design, Synthesis, and Biological Evaluation of 99m Tc‐Labeled Thalidomide Analogs as Novel Tumor‐Targeting Radiopharmaceuticals
Journal of Labelled Compounds and Radiopharmaceuticals · 2026
DOI: 10.1002/jlcr.70045 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Labelled Compounds and Radiopharmaceuticals, 2026. Verfasst von Hassan M Rashed und 5 weiteren Autor:innen. Beteiligte Einrichtung: Labeled Compounds Department, Hot Laboratories and Waste Management Center, Egyptian Atomic Energy Authority, Cairo, Egypt. Hauptthemen laut MEDLINE: Radiopharmaceuticals, Thalidomide, Technetium, Drug Design. Die Arbeit nennt 31 Literaturangaben.
Abstract (Originalsprache)
This study aimed to develop tumor‐selective radiopharmaceuticals for noninvasive imaging using three thalidomide analogs: N‐(2,6‐dioxopiperidin‐3‐yl)‐2‐((3‐ethyl‐7‐nitro‐4‐oxo‐3,4‐dihydroquinazolin‐2‐yl)thio)acetamide (DPDQA), 2‐amino‐N‐(2,6‐dioxopiperidin‐3‐yl)benzamide (ADPB), and 2‐(2‐chloroquinazolin‐4‐yl)hydrazine‐1‐carboxamide (CQHC). These compounds were radiolabeled with 99m Tc via a direct labeling method using sodium dithionite (Na 2 S 2 O 4 ) as a reducing agent. Optimal labeling conditions were determined by evaluating pH, ligand/reducing agent amounts, reaction time, and temperature. Radiochemical purity reached 92% ± 0.31% for 99m Tc‐DPDQA (pH 8, 500‐μg ligand, 500‐mg Na 2 S 2 O 4 , 15 min), 89.8% ± 0.128% for 99m Tc‐ADPB (pH 7, 800‐μg ligand, 25‐mg Na 2 S 2 O 4 , 15 min), and 92% ± 0.16% for 99m Tc‐CQHC (pH 10, 200‐μg ligand, 150‐mg Na 2 S 2 O 4 , 30 min). All complexes demonstrated good in vitro stability up to 24 h. In vivo biodistribution studies in tumor‐bearing mice revealed high tumor uptake ( T / NT ratios: 19.75, 6.18, and 22.72 for 99m Tc‐DPDQA, 99m Tc‐ADPB, and 99m Tc‐CQHC, respectively), with renal excretion as the primary clearance pathway. These results highlight the potential of 99m Tc‐labeled thalidomide analogs as selective tumor‐imaging agents outperforming existing agents like 99m Tc‐TEPA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Labeled Compounds Department, Hot Laboratories and Waste Management Center, Egyptian Atomic Energy Authority, Cairo, Egypt.
- Radiation Protection Department, Nuclear and Radiological Regulatory Authority, Egyptian Atomic Energy Authority, Cairo, Egypt.
- Pharmaceutical Medicinal Chemistry and Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.
- Radioactive Isotopes and Generator Department, Hot Laboratories and Waste Management Center, Egyptian Atomic Energy Authority, Cairo, Egypt.
ORCID-Profile: Hassan M Rashed, Abdallah E Abdallah, Mohamed Ayman El-Zahabi, Tamer M Sakr
Zitieren
APA
Rashed, H. M., Mohamed, A. M. H., Eissa, I. H., Abdallah, A. E., El-Zahabi, M. A., & Sakr, T. M. (2026). Design, Synthesis, and Biological Evaluation of 99m Tc‐Labeled Thalidomide Analogs as Novel Tumor‐Targeting Radiopharmaceuticals. Journal of Labelled Compounds and Radiopharmaceuticals. https://doi.org/10.1002/jlcr.70045
Vancouver
Rashed HM, Mohamed AMH, Eissa IH, Abdallah AE, El-Zahabi MA, Sakr TM. Design, Synthesis, and Biological Evaluation of 99m Tc‐Labeled Thalidomide Analogs as Novel Tumor‐Targeting Radiopharmaceuticals. Journal of Labelled Compounds and Radiopharmaceuticals. 2026. doi:10.1002/jlcr.70045
BibTeX
@article{Rashed2026,
author = {Rashed, Hassan M and Mohamed, Ashraf Mohamed Hamed and Eissa, Ibrahim H and Abdallah, Abdallah E and El-Zahabi, Mohamed Ayman and Sakr, Tamer M},
title = {Design, Synthesis, and Biological Evaluation of 99m Tc‐Labeled Thalidomide Analogs as Novel Tumor‐Targeting Radiopharmaceuticals},
journal = {Journal of Labelled Compounds and Radiopharmaceuticals},
year = {2026},
doi = {10.1002/jlcr.70045}
}
EUVIMED